NCT06458803View on ClinicalTrials.gov

Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

May 6, 2013

Primary Completion Date

May 11, 2023

Study Completion Date

November 19, 2023

Conditions
Refractory ThrombocytopeniaConnective Tissue Diseases
Interventions
DRUG

Eltrombopag

patients receive oral eltrombopag at 25 to 75 mg once daily according to disease severity，with the treatment of DMARDs at minimal or routine dosages.

All Listed Sponsors
lead

Tongji Hospital

OTHER

NCT06458803 - Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease | Biotech Hunter | Biotech Hunter